Document is current
Any future updates will be listed below
-
Authors
Zboralski, Dirk https://orcid.org/0000-0002-2224-2452
Hoehne, Aileen
Bredenbeck, Anne
Schumann, Anne
Nguyen, Minh
Schneider, Eberhard
Ungewiss, Jan
Paschke, Matthias
Haase, Christian
von Hacht, Jan L.
Kwan, Tanya
Lin, Kevin K.
Lenore, Jan
Harding, Thomas C.
Xiao, Jim
Simmons, Andrew D.
Mohan, Ajay-Mohan
Beindorff, Nicola
Reineke, Ulrich
Smerling, Christiane
Osterkamp, Frank
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (16GW0194)
- License Information
-
More Information
Article History
Received: 15 February 2022
Accepted: 10 May 2022
First Online: 24 May 2022
Declarations
:
: All animal experiments were carried out under licenses approved by the respective authorities and in compliance with guidelines on animal welfare.
: D. Zboralski, A. Hoehne, A. Bredenbeck, A. Schumann, E. Schneider, J. Ungewiss, M. Paschke, C. Haase, J.L. von Hacht, U. Reineke, C. Smerling, and F. Osterkamp are employees of 3B Pharmaceuticals GmbH and are named inventors of FAP-2286. M. Paschke, U. Reineke, C. Smerling, and F. Osterkamp are cofounders of 3B Pharmaceuticals GmbH. M. Nguyen, J. Lenore, T. Kwan, K.K. Lin, T.C. Harding, J. Xiao, and A.D. Simmons are or have been employees of Clovis Oncology, Inc., and may own stock or have stock options in the company.
